Predictive value of fibrinogen for early neurological deterioration in large-artery atherosclerotic cerebral infarction

Background & Objective: To evaluate the predictive value of fibrinogen at admission for early neurological deterioration (END) in patients with large artery atherosclerotic (LAA) stroke without reperfusion therapy. Fibrinogen, a glycoprotein crucial for clotting, is associated with worse outcomes in ischemic stroke patients. While its connection with thrombolytic therapy’s prognosis is recognized, its predictive role for non-thrombolytic-treated patients is less clear. The objective of this study is to evaluate the predictive value of fibrinogen at admission for early neurological deterioration (END) in patients with large artery atherosclerotic (LAA) stroke without reperfusion therapy. Methods: This retrospective case-control study included consecutive inpatients with LAA stroke admitted within 72 h of onset at the Fifth Affiliated Hospital of Sun Yat-Sen University between January 2021 and December 2021. An increase of >2 in the National Institutes of Health Stroke Scale (NIHSS) within 7 days after admission was defined as END. Results: This study included 179 patients (121 males); the mean age was 62.67±13.51 years. There were 42 and 137 patients in the END and non-END groups. The NIHSS score at admission was higher in the END group than in the non-END group, the fibrinogen levels were higher, and the uric acid levels were lower (all P<0.05). NIHSS at admission (OR=1.086, 95%CI: 1.001-1.179), fibrinogen levels (OR=2.182, 95%CI: 1.286- 3.702), and uric acid levels (OR=0.995, 95%CI=0.990-0.999) were independently associated with END. Receiver-operating characteristic curve analysis suggested that the sensitivity, specificity, and area under the curve for fibrinogen for END were 62.9%, 78.1%, and 0.730 (95% CI: 0.532-0.828, P<0.009), respectively. Conclusions: Elevated fibrinogen is independently associated with END in patients with LAA stroke without reperfusion therapy.